ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ALKS Stock Price » ALKS Stock News

Alkermes Share News

 Alkermes (mm) Stock Price
ALKS Stock Price
 Alkermes (mm) Stock Chart
ALKS Stock Chart
 Alkermes (mm) Stock News
ALKS Stock News
 Alkermes (mm) Company Information
ALKS Company Information
 Alkermes (mm) Stock Trades
ALKS Stock Trades

Amylin, MannKind Shares Rise On Diabetes Data Releases

DOW JONES NEWSWIRES Drug companies unleashed a glut of research about diabetes treatments Friday, including data about the popular Byetta treatment and longer-acting versions of it, which boosted Amylin Pharmaceuticals Inc.'s (AMLN) shares after hours, as well as encouraging statements about an inhaled-insulin treatment from MannKind Corp. (MNKD). The releases came as the American Diabetes Association's annual scientific meeting kicked off in San Diego. Amylin, Eli Lilly & Co. (LLY) and Alkermes Inc. (ALKS) released two reports about Bydureon, a once-weekly version of the already-approved diabetes drug Byetta. The Food and Drug Administration declined to approve Bydureon in October, substantially delaying a widely expected approval. Friday, results from one Bydureon study suggested the treatment didn't slow the heart rate in patients with type-2 diabetes. Other Bydureon studies showed that type-2 patients showed improvement in glycemic control and lost weight over the course of several years, the companies said. The three companies also released data on an investigational, once-monthly injectable suspension formulation of the drug. They said a midstage study indicated "substantial improvement" in glycemic control with modest weight loss. Regarding Byetta, Amylin and Lilly reported that a retrospective analysis of more than 778,000 patients showed adding Byetta injection to pre-existing diabetes treatment regimens was associated with reduced chances for heart failure. On its own, Amylin said a study of another already approved diabetes drug, Symlin, showed the treatment helped reduce the average level of blood sugar, insulin use and body weight in type-1 patients who used insulin pumps. Amylin shares rose 5.7% to $12.50 after hours. Alkermes shares rose 0.4% to $17.37, and Lilly's weren't active. MannKind reported two separate sets of findings about its inhaled insulin treatment, Afrezza. The company has been trying to win FDA approval for the treatment, but investors haven't been impressed by the rate of progress. Friday, it said two studies "further substantiate" that treatment with Afrezza doesn't cause excess cardiovascular events, like heart attack or artery disease, in type-1 or type-2 patients. It also said a study showed type-1 patients who received Afrezza combined with basal insulin had a more positive view about insulin therapy than those who used a standard therapy with basal insulin. MannKind shares were up 9% at $4.35 after hours. Through the close, the stock has declined 51% so far this year. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; joan.solsman@dowjones.com

Stock News for Alkermes (ALKS)
DateTimeHeadline
11/15/201309:01:37HBK Investments LP 3Q 13F: Largest Eliminations
11/15/201309:01:27HBK Investments LP 3Q 13F: Largest Purchases
11/15/201309:01:27HBK Investments LP 3Q 13F: Largest Sales
11/15/201309:01:27HBK Investments LP 3Q 13F: Largest Eliminations -2-
11/15/201308:22:25Janus Capital Management 3Q 13F: Largest Purchases -2-
11/15/201308:22:24Janus Capital Management 3Q 13F: Holdings As Of -2-
11/15/201308:22:24Janus Capital Management 3Q 13F: Largest Purchases
11/15/201308:22:23Janus Capital Management 3Q 13F: Holdings As Of Sep 30
10/10/201309:29:34U.S. Hot Stocks Futures: Hot Stocks to Watch
05/31/201209:19:14US HOT STOCK FUTURES: HOT STOCKS TO WATCH
01/30/201217:42:15US Stocks Edge Lower As Europe's Debt Flashpoints Weigh
01/30/201208:02:33US Stock Futures Lower On Renewed Worries Over Greece
01/27/201216:12:26FDA Approves Amylin's Bydureon Diabetes Drug After Delays
07/28/201109:30:07Amylin, Eli Lilly And Alkermes Submit Reply To FDA On Bydureon
07/27/201105:30:27CORRECT: Elan Confirms Outlook As Quarterly Net Loss Narrows
07/18/201115:19:27Alkermes Sees Sales Growth After Merger With Elan Drug Tech
07/12/201110:09:05Elan To Close Pennsylvania Site Ahead Of Unit Sale To Alkermes
06/24/201119:46:35Amylin, MannKind Shares Rise On Diabetes Data Releases
06/21/201107:02:05Lilly, Amylin, Alkermes Diabetes Drug Gets EU Approval
05/09/201104:46:15Elan Sells EDT Unit To Alkermes To Generate Cash, Cut Debt

Alkermes and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad